Haloxon

Haloxon

SCHEMBL167194

Cc1c(Cl)c(=O)oc2cc(OP(=O)(OCCCl)OCCCl)ccc12

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.65
ALDH1A1 P00352 7/20 0.65
HPGD P15428 6/20 0.65
CA12 O43570 2/20 0.65
CA1 P00915 2/20 0.65
CA4 P22748 2/20 0.65
CA5A P35218 2/20 0.65
CA7 P43166 2/20 0.65
CA5B Q9Y2D0 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
CA3 P07451 1/20 0.65
CYP3A4 P08684 1/20 0.65
CA6 P23280 1/20 0.65
CA9 Q16790 1/20 0.65
CA13 Q8N1Q1 1/20 0.65
CA14 Q9ULX7 1/20 0.65
GAA P10253 4/20 0.61
HSD17B10 Q99714 2/20 0.61
LMNA P02545 2/20 0.57
ALPL P05186 9/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL669657 0.89 KDM4E (0.77) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL3265953 0.88 KDM4E (0.62) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL4104045 0.79 KDM4E (0.65) KDM4EALDH1A1HPGDCA12CA1
Coumaphos SCHEMBL29363459 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDCA12CA1
Coumaphos SCHEMBL9283960 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDCA12CA1
Coumaphos SCHEMBL120173 0.79 KDM4E (1.00) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL38663564 0.78 KDM4E (0.70) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL4104048 0.78 KDM4E (0.70) KDM4EALDH1A1HPGDCA12CA1
SCHEMBL6150849 0.77 KDM4E (0.69) KDM4EALDH1A1HPGDCA12CA1
Coumaphos SCHEMBL9812694 0.77 KDM4E (0.89) KDM4EALDH1A1HPGDCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1792 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4586826-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL In the Bowl Animal Health, Inc. (US) 2025-07-23 EP claimed
WO-2024059837-A1 FEED AND METHODS FOR CONTROLLING HEARTWORM INFECTIONS IN A MAMMAL IN THE BOWL ANIMAL HEALTH, INC. (US) 2024-03-21 WO claimed
WO-2023126969-A1 ORAL FILMS OF ANIT-PARASITIC DRUGS LAURUS LABS LIMITED (IN) 2023-07-06 WO claimed
CN-111972277-B Method for breeding black wheat germplasm with different genetic backgrounds by utilizing blue dwarf male sterile and purple wheat 淄博爱民种业有限公司 2022-07-26 CN claimed
CN-111972277-A Method for breeding black wheat germplasm with different genetic backgrounds by utilizing blue dwarf male sterile and purple wheat 淄博爱民种业有限公司 2020-11-24 CN claimed
EP-1675474-B9 PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION NOVARTIS TIERGESUNDHEIT AG (CH) 2018-12-05 EP claimed
EP-1675474-B2 PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION NOVARTIS TIERGESUNDHEIT AG (CH) 2016-12-07 EP claimed
US-9345108-B2 Self-adaptive brightness sensor light, brightness sensor module, and brightness-adjusting method of the same IR-TEC INTERNATIONAL LTD. (TW) 2016-05-17 US claimed
US-20150216015-A1 SELF-ADAPTIVE BRIGHTNESS SENSOR LIGHT, BRIGHTNESS SENSOR MODULE, AND BRIGHTNESS-ADJUSTING METHOD OF THE SAME IR-TEC INTERNATIONAL LTD. (TW) 2015-07-30 US claimed
WO-2015089530-A1 EXTENDED-RELEASE ORAL DOSAGE FORM CONTAINING MORPHINE AND NALOXONE G.L. PHARMA GmbH (AT) 2015-06-25 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
JP-2007500004-A 2007-01-11 JP claimed
US-20060257966-A1 Medium for detection and identification of micro-organisms BIOMERIEUX (FR) 2006-11-16 US claimed
US-20060222684-A1 Palatable ductile chewable veterinary composition ELANCO TIERGESUNDHEIT AG (CH) 2006-10-05 US claimed
CN-1829448-A Palatable ductile chewable veterinary composition NOVARTIS AG (CH) 2006-09-06 CN claimed
EP-1675474-A1 PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION Novartis AG (CH) 2006-07-05 EP claimed
CN-1583174-A Long-term injection containing ethylcellulose and fatty acid ester WANG YUWAN (CN) 2005-02-23 CN claimed
WO-2005013714-A1 PALATABLE DUCTILE CHEWABLE VETERINARY COMPOSITION NOVARTIS AG (CH) 2005-02-17 WO claimed
CN-1444925-A Long acting injection containing ethyl cellulose for animal WANG YUWAN (CN) 2003-10-01 CN claimed
EP-0651055-A2 Uses of modified cholinesterase and compositions containing them State of Israel Represented by the Prime Minister's Office The Israel Institute for Biological Research (IL) 1995-05-03 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060222684-A1 Palatable ductile chewable veterinary composition PIGO, TAS2R41, TAS2R30 KDM4E 3180/4885ALDH1A1 3866/4885HPGD 889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.